Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline
J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline
J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline
Submitted by
admin
on January 4, 2017 - 10:46am
Source:
Fierce Pharma
News Tags:
JNJ
Actelion
M&A
Headline:
J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline
Do Not Allow Advertisers to Use My Personal information
